A recent study indicates that patients who stop using popular weight-loss injections like Wegovy and Mounjaro tend to recover lost weight at a significantly accelerated pace than those who end conventional diet and exercise plans.
Published data in a major medical journal shows that while obese individuals frequently drop substantial amounts of their total mass while on the medication, the mass is regained at an average rate of nearly a kilo each month after stopping.
"People buying such treatments must be cognizant of the potential of rapid rebound weight gain when the therapy ends," cautioned researcher Dr. Susan Jebb.
That rate of recovery implies a reversion to original mass within about a year and a half.
Weighing Treatments
The study, which examined dozens of studies involving thousands of patients, contrasted the effects of GLP-1 agonists with conventional dieting.
Researchers point out that people who shed pounds through diet and exercise usually have a less rapid creep back—perhaps 100 grams monthly—once they finish.
The Reason for the Rapid Regain
Experts believe the mode of action of the drugs accounts for the accelerated rebound.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing GLP-1 levels several times higher than normal might result in the body to produce less of its endogenous hormone, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication results in hunger is uncontrolled, making binge eating much more probable."
A Lifelong Disease?
Medical guidelines suggest the injections for individuals with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Many experts argue that, considering the likelihood of relapse, the treatment should be considered long-term.
This perspective is supported by drug manufacturers, who state that the findings "emphasize the long-term character of obesity," similar to managing diseases like hypertension.
Patient Testimonies
Users who have stopped the medication explain a powerful return of hunger.
"It felt as if something activating and you're instantly starving," said a patient.
This challenge is compounded if users have not developed permanent lifestyle or habit changes during therapy.
Growing Adoption
Figures indicate that a significant number of adults in the UK have tried weight-loss jabs in the past year, with demand being substantial.
- Adoption is more common among women compared to men.
- The middle-aged demographic shows the highest level of interest.
- Many obtain the drugs through private prescriptions rather than the NHS.
In conclusion, researchers stress that while GLP-1 drugs are potent tools for shedding pounds, they are not a standalone fix and maintained weight loss likely depends on ongoing lifestyle support.
